Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Si-Hang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Pemphigoid, Bullous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Background
Bullous pemphigoid (BP) affects older adults and treatment is often limited by corticosteroid toxicity. Evidence for stapokibart in BP is limited.
Objectives
To describe the clinical outcomes and safety of stapokibart-based combination therapy in BP.
Methods
We retrospectively reviewed consecutive patients with BP who received stapokibart-based combination therapy at Peking Union Medical College Hospital between October 2024 and October 2025, and had a follow-up period of ≥ 4 months. Stapokibart was administered as a 600-mg loading dose, followed by 300 mg every 2 weeks. Outcomes included time to disease control; time to Bullous Pemphigoid Disease Area Index (BPDAI) activity score of 0; time to complete remission (CR) on minimal therapy; adverse events; and changes in BPDAI activity, pruritus numerical rating scale (NRS), anti-BP180 titres, eosinophil counts and concomitant corticosteroid exposure throughout the follow-up period.
Results
Twelve patients were enrolled, with a median age of 77.5 years and a median follow-up period of 217 days. All received concomitant Tripterygium glycosides, and 7 of 12 (58%) also received oral corticosteroids at stapokibart initiation. All patients achieved disease control within a median time of 14.5 days. Eleven of the 12 patients (92%) reached disease control within 4 weeks. A BPDAI activity score of 0 was reached in all patients (median 65.5 days). Seven patients (58%) achieved CR on minimal therapy (median 176 days among responders). During follow-up, BPDAI activity, pruritus NRS, eosinophil counts, anti-BP180 titres and prednisone doses all decreased. One patient reported temporary fatigue and later developed herpes zoster. No patients stopped treatment throughout the study.
Conclusions
Stapokibart-based combination therapy was associated with rapid short-term disease control and clinical improvement in this small retrospective cohort of patients with BP. Given the limited sample size and frequent concomitant therapy, these preliminary findings require confirmation in larger controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Si-Hang Wang, Hanlin Zhang, Si-Zhe Li, Ya-Gang Zuo
Zitieren
APA
Wang, S. H., Liu, S. H., Zhang, J., Zhang, H., Wang, Y., Li, S. Z., & Zuo, Y. G. (2026). Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag269
Vancouver
Wang SH, Liu SH, Zhang J, Zhang H, Wang Y, Li SZ, et al. Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag269
BibTeX
@article{Wang2026,
author = {Wang, Si-Hang and Liu, Si-Han and Zhang, Jie and Zhang, Hanlin and Wang, Yan and Li, Si-Zhe and Zuo, Ya-Gang},
title = {Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag269}
}
EUVIMED